Medical/Pharmaceuticals
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a collaboration with Microsoft to accelerate the delivery of AI-powered healthcare solutions. In conjunction with their recent acquisition of V...
2025-07-02 21:00
2365
Bon Announces Breakthrough Order for $16 Million Gut-Health Products
XI'AN, China, July 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solutions provider in the natural, health, and personal care industries, today announced a non-exclusive sales distribution agreement with Beijing Huahai Keyuan Te...
2025-07-02 20:00
3945
[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria
* Gram-negative bacterial infections are becoming an increasingly serious global health issue * U.S. patent applications filed for three novel drug candidates: PKL200, TSL2200, and EAL2200 * Continued diversification of business initiatives to address Gram-negative bacterial threats BOSTON ...
2025-07-02 20:00
2075
Arbele Wins Top Prize at BCIC's 4th Annual Biomedical Pitch Competition
BOSTON, July 2, 2025 /PRNewswire/ -- Arbele Limited, a Hong Kong-based biotech company, was awarded first place at the 4th Biomedical Pitch Competition, hosted by the Boston Capital Investment Club (BCIC). Selected from over 170 companies across the U.S. andAsia, Arbele stood out for its groundbr...
2025-07-02 16:19
1767
Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
* As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52 weeks of follow-up. In Cohort 2, 7 patients completed 52 weeks of follow-up. * The updated data showed that EVER001 was well-tolerated and efficacious ...
2025-07-02 15:33
2169
Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform
* BioStar Capital and Cue Growth co-lead financing to accelerate pivotal trial readiness and expand the ventricular tachycardia (VT) treatment market * New board leadership reflects Field's momentum and readiness for pivotal execution CARDIFF-BY-THE-SEA, Calif., July 1, 2025 /PRNewswire/ -- Fi...
2025-07-01 22:47
2635
TraceLink's MINT Named "Supply Chain Transparency Solution of the Year" in 2025 SupplyTech Breakthrough Awards
The award recognizes MINT for enabling real-time, end-to-end visibility across critical supply chain transactions and processes BOSTON, July 1, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, today announced that its Mu...
2025-07-01 22:42
2417
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics
* Real-time analytics that empower clinical decision-making and pandemic preparedness * Global unveiling at ADLM 2025 in Chicago to initiate business partnerships * Powered by AI and syndromic PCR to enable early detection and predictive insights SEOUL, South Korea, July 1, 2025 /PRNewswire/...
2025-07-01 22:09
3516
FAIR PLAY MENARINI INTERNATIONAL AWARD, LUIS FIGO JOINS THE GREAT SPORTS STARS ACKNOWLEDGED IN 2025
FLORENCE, Italy, July 1, 2025 /PRNewswire/ -- Surprises never end when it comes to theFair Play Menarini International Award: Luís Figo, European football legend and true icon of sporting integrity, will be among the awardees of the 29th edition of the event, taking place onJuly 2nd and 3rd in Fl...
2025-07-01 21:10
2788
Metabolon's Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)
Combining metabolomics, gut microbiome, and clinical data may help prevent and personalize the treatment of type 2 diabetes MORRISVILLE, N.C., July 1, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, d...
2025-07-01 21:00
1937
Anta Group's HEMIN Foundation Releases First Report Focusing on Medical Donations Over Three Years: Cumulative Donations Exceed RMB 650 Million
JINJIANG, China, July 1, 2025 /PRNewswire/ -- On July 1, Anta Group's HEMIN Foundation released its first report covering the years 2021–2024. The Foundation was established in December 2021 with an announcement of RMB 10 billion donation from Anta Group's founding family. Upholding the charitabl...
2025-07-01 20:18
3108
WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing
SHANGHAI and SINGAPORE, July 1, 2025 /PRNewswire/ -- On June 30, WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the mechanical completion of its ma...
2025-07-01 17:44
4262
Pioneering Global Presence, Empowering the World - Zuowei Technology Shining at WHX Miami Medical Expo
SHENZHEN, China, July 1, 2025 /PRNewswire/ -- From June 11 to 13, the 2025 WHX Miami Medical Expo (formerly known as FIME), the annual grand event of the medical industry in the Americas, was held at theMiami Beach Convention Center. As one of the largest and most influential professional exhibit...
2025-07-01 16:32
2318
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement with Shanghai He...
2025-07-01 13:40
2213
CentraLlVF Launches New Guaranteed Egg Donation Programs Through CEB and AWEB
Expanded blastocyst-guarantee programs now available through two CentraLlVF brands, supporting a wider range of Australian recipients LONDON, July 1, 2025 /PRNewswire/ -- CentraLlVF, a leading Australian provider of donor egg solutions, is proud to announce important program updates across both...
2025-07-01 07:00
1723
Wingderm USA Takes the Lead at TAS 2025, Cementing Its Local Presence in the U.S.
BEIJING, June 30, 2025 /PRNewswire/ -- Wingderm®, a leading innovator in energy-base medical aesthetic technologies, officially made its debut at The Aesthetic Show (TAS) 2025, held fromJune 27 to 29 in Las Vegas. This marks a key step as the brand grows in the U.S. medical aesthetic market. A...
2025-07-01 00:35
2100
AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
TOKYO, June 30, 2025 /PRNewswire/ -- AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies for hematologic cancers and autoimmune diseases, today announced it has been awarded a grant of up to $...
2025-06-30 22:34
1808
Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs
* "The next decade will focus on securing strong growth momentum by strengthening product competitiveness and profitability" * First technology-special listed company to join the Corporate Value-Up Program… "We will grow by faithfully responding to stakeholder needs and expectations." YONGIN,...
2025-06-30 21:00
2316
Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
Interim analysis planned for January 2026 with final trial results in late 2026 Highlights: * With the 100th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed forJanuary 2026 and the timeline for final results reconfirmed for late 2026 * An...
2025-06-30 20:30
1845
Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals
TOKYO, June 30, 2025 /PRNewswire/ -- Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc. ("Curadh") announced plans to enter a strategic partnership, including a Joint Venture to broadly advance the global development of Astatine-211 (At-211) based radiopharmaceuticals. The collaboration co...
2025-06-30 20:00
1855
Week's Top Stories
Most Reposted
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 328 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 310 media titles]
2026-02-26 19:57
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 309 media titles]
2026-02-26 09:30
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
Most Read
NYSE Content Update: AI Data Platform DDN Appoints Guido Torrini as Finance Chief
2026-02-24 22:08
5026
